

Special Issue

New Advances in Urothelial Cancer: Diagnosis, Therapy and Prognosis

Message from the Guest Editors

Urothelial cancers are the sixth most common tumors in developed countries. Bladder tumors account for 90–95% of UCs and are the most common urinary tract malignancy; by contrast, upper urinary tract UCs are uncommon and account for only 5–10% of UCs. In recent years new urothelial biomarkers have been proposed in their diagnostic and prognostic role; liquid biopsy has arisen as an important tool for urothelial cancer early detection and prognosis, identifying different pathways of cell signaling, proliferation, and apoptosis changes in tumor biology and progression. New immunotherapy agents based on checkpoint inhibitor-optimized cancer therapy and oncologic outcomes have emerged, and device-assisted therapy (EMDA, thermochemotherapy) has been outlined as a preserving approach to recurrent non-muscle invasive bladder disease, while the minimally invasive approach of robotic surgery has been found to reduce adverse events and hospital stay when major urologic surgery is needed. The purpose of this Special Issue is to identify and summarize the latest innovations in urothelial cancer management, overcome present challenges and open new paths to future strategies.

Guest Editors

Prof. Pierfrancesco Bassi

Department of Urology, Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS di Roma, Università Cattolica del Sacro Cuore di Roma, Largo Agostino Gemelli 8, 00168 Rome, Italy

Dr. Giuseppe Palermo

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Deadline for manuscript submissions

closed (13 September 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/117021

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)